Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts

Journal of Cellular Physiology

Volumn 228, Issue 3, 2013, Pages 640-645

  Esposito, Vincenzo ^a   Verdina, Alessandra ^b   Manente, Lucrezia ^c   Spugnini, Enrico P ^b   Viglietti, Rosaria ^a   Parrella, Roberto ^a   Pagliano, Pasquale ^d   Parrella, Giovanni ^a   Galati, Rossella ^b   De Luca, Antonio ^c   Baldi, Alfonso ^c   Montesarchio, Vincenzo ^a   Chirianni, Antonio ^a  

^a Third Division of Infection Diseases   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d AORN dei Colli   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; DOXORUBICIN; GELATINASE A; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER REGRESSION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARBAMATES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVATION; HIV PROTEASE INHIBITORS; HUMANS; LIVER NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS C-AKT; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 84870475903     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24173     Document Type: Article

References (37)

1. Abou-Alfa KG, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, Leung T, Gansukh B, Saltz LB. 2010. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: A randomized trial. JAMA 304:2154-2160.
2. Ashburn TT, Thor KB. 2004. Drug repositioning: Identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3:673-683.
3. Baldi A, De Luca A, Morini M, Battista T, Felsani A, Baldi F, Catricalà C, Amantea A, Noonan DM, Albini A, Natali PG, Lombardi D, Paggi MG. 2002. The HtrA1 serine protease is down-regulated during human melanoma progression and represses growth of metastatic melanoma cells. Oncogene 21:6684-6688.
4. Berretta M, Lleshi A, Di Benedetto F, Bearz A, Spina M, Tirelli U. 2006. Oxaliplatin and capecitabine (Xelox) in association with highly active antiretroviral therapy in advanced hepatocarcinoma HIV/HCV-infected patients. Ann Oncol 17:1176-1177.
5. Bono C, Karlin L, Harel S, Mouly E, Labaume S, Galicier L, Apcher S, Sauvageon H, Fermand JP, Bories JC, Arnulf B. 2012. The HIV-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the multiple myeloma cells proliferation in vitro and in vivo. Haematologica 97:1101-1109.
6. Braun N. 2005. Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin. Semin Liver Dis 25:33-51.
7. Cheung TW. 2004. AIDS-related cancer in the era of highly active antiretroviral therapy (HAART): A model of the interplay of the immune system, virus, and cancer. "On the offensive-The Trojan Horse is being destroyed"-Part A: Kaposi's sarcoma. Cancer Invest 22:774-786.
8. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, Rapiti E, Levi F, Jundt G, Fisch T, Bordoni A, De Weck D, Franceschi S, Swiss HIV Cohort. 2005. Cancer risk in the Swiss HIV Cohort Study: Associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer I 97:425-432.
9. Esposito V, Palescandolo E, Spugnini EP, Montesarchio V, De Luca A, Cardillo I, Cortese G, Baldi A, Chirianni A. 2006. Evaluation of antitumoral properties of the protease inhibitor indinavir in a murine model of hepatocarcinoma. Clin Cancer Res 12:2634-2639.
10. Gaedicke S, Firat-Geier E, Constantiniu O, Lucchiari-Hartz M, Freudenberg M, Galanos C, Niedermann G. 2002. Anti-tumor effect of the human immunodeficiency virus protease inhibitor ritonavir: Induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. Cancer Res 62:6901-6908.
11. Gupta AK, Cerniglia GJ, Mick R, McKenna WG, Muschel RJ. 2005. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res 65:8256-8265.
12. Ikezoe T, Daar ES, Hisatake J, Taguchi H, Koeffler HP. 2000. HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells. Blood 96:3553-3559.
13. Ikezoe T, Hisatake Y, Takeuchi T, Ohtsuki Y, Yang Y, Said JW, Taguchi H, Koeffler HP. 2004a. HIV-1 protease inhibitor, ritonavir: A potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res 64:7426-7431.
14. Ikezoe T, Saito T, Bandobashi K, Yang Y, Koeffler HP, Taguchi H. 2004b. HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2. Mol Cancer Ther 3:473-479.
15. Jiang W, Mikochik PJ, Ra JH, Lei H, Flaherty KT, Winkler JD, Spitz FR. 2007. HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest. Cancer Res 67:1221-1227.
16. Kessenbrock K, Plaks V, Werb Z. 2010. Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell 141:52-67.
17. Kincaid L. 2007. Modern HAART decreases cancers in children with HIV. Lancet Oncol 8:103.
18. Laurence J. 2003. Impact of HAART on HIV-linked malignancies. AIDS Reader 13:202.
19. Long JL, Engels EA, Moore RD, Gebo KA. 2008. Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS 22:489-496.
20. Monini P, Toschi E, Sgadari C, Bacigalupo I, Palladino C, Carlei D, Barillari G, Ensoli B. 2006. The use of HAART for biological tumour therapy. J HIV Ther 11:53-56.
21. Murillas J, Del Rio M, Riera M, Vaquer P, Salas A, Leyes M, Angeles Ribas M, Peñaranda Vera M, Villalonga C. 2005. Increased incidence of hepatocellular carcinoma (HCC) in HIV-1 infected patients. Eur J Intern Med 6:113-115.
22. O'Connor KA, Roth BL. 2005. Finding new tricks for old drugs: An efficient route for public-sector drug discovery. Nat Rev Drug Discov 4:1005-1014.
23. Pajonk F, Himmelsbach J, Riess K, Sommer A, Mc Bride WH. 2002. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res 62:5230-5235.
24. Panos G, Samonis G, Alexiou VG, Kavarnou GA, Charatsis G, Falagas ME. 2008. Mortality and morbidity of HIV infected patients receiving HAART: A cohort study. Curr HIV Res 6:257-260.
25. Perboni G, Costa P, Fibbia GC, Morandini B, Scalzini A, Tagliani A, Cengarle R, Aitini E. 2010. Sorafenib therapy for hepatocelluar carcinoma in an HIV-HCV coinfected patient: A case report. Oncologist 15:142-145.
26. Pineda JA, Pérez-Elías MJ, Peña JM, Lugue I, Rodrìguez-Alcantara F, Fosamprenavir Expanded Access Program Group. 2008. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens. HIV Clin Trials 9:309-313.
27. Plastaras JP, Vapiwala N, Ahmed MS, Gudonis D, Cerniglia GJ, Feldman MD, Frank I, Gupta AK. 2008. Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans. Cancer Biol Ther 7:628-635.
28. Pore N, Gupta AK, Cerniglia GJ, Maity A. 2006. HIV protease inhibitors decrease VEGF/HIF-1α expression and angiogenesis in glioblastoma cells. Neoplasia 8:889-895.
29. Puoti M, Bruno R, Soriano V, Donato F, Gaeta GB, Quinzan GP, Precone D, Gelatti U, Asensi V, Vaccher E, HIV HCC Cooperative Italian-Spanish Group. 2004. Hepatocellular carcinoma in patients: Epidemiological features, clinical presentation and outcome. AIDS 18:2285-2293.
30. Qin XQ, Tao N, Dergay A, Moy P, Fawell S, Davis A, Wilson JM, Barsoum J. 1998. Interferon-ß gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc Natl Acad Sci USA 95:14411-14416.
31. Rosenthal E, Poirée M, Pradier C, Perronne C, Salmon-Ceron D, Geffray L, Myers RP, Morlat P, Pialoux G, Pol S, Cacoub P, GERMIVIC Joint Study Group. 2003. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 17:1803-1809.
32. Seminari E, De Bona A, Gentilini G, Galli L, Schira G, Gianotti N, Uberti-Foppa C, Soldarini A, Dorigatti F, Lazzarin A, Castagna A. 2007. Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment. J Antimicrob Chemother 60:831-836.
33. Serraino D, Boschini A, Carrieri P, Pradier C, Dorrucci M, Maso L, Ballarini P, Pezzotti P, Smacchia C, Pesce A, Ippolito G, Franceschi S, Rezza G. 2000. Cancer risk among men with, or at risk of, HIV infection in southern Europe. AIDS 14:553-559.
34. Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, Palladino C, Leone P, Bugarini R, Malavasi L, Cafaro A, Falchi M, Valdembri D, Rezza G, Bussolino F, Monini P, Ensoli B. 2002. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 8:225-232.
35. Stetler-Stevenson WG. 1999. Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention. J Clin Invest 103:1237-1241.
36. Wickenden JA, Watson CJ. 2010. Key signalling nodes in mammary gland development and cancer. Signalling downstream of PI3 kinase in mammary epithelium: A play in 3 Akts. Breast Cancer Res 12:202.
37. Yang Y, Ikezoe T, Takeuchi T, Adachi Y, Ohtsuki Y, Takeuchi S, Koeffler HP, Taguchi H. 2005. HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling. Cancer Sci 96:425-433.